Patents by Inventor Jacalyn H. Pierce

Jacalyn H. Pierce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions of alpha platelet derived growth factor receptor nucleic acid and protein and method of making
    Patent number: 7427671
    Abstract: A DNA sequence which encodes a human type ? platelet derived growth factor receptor protein which preferentially binds to the AA homodimer and AB heterodimer forms of platelet derived growth factor and also binds the BB homodimer at high affinity, is described. Substantially pure human a platelet derived growth factor receptor protein and methods for recombinantly producing human ? platelet derived growth factor receptor protein are also described.
    Type: Grant
    Filed: May 11, 1995
    Date of Patent: September 23, 2008
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services
    Inventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
  • Methods for identifying alpha PDGFR agonists and antagonists
    Patent number: 7252929
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.
    Type: Grant
    Filed: November 3, 2003
    Date of Patent: August 7, 2007
    Assignee: United States of America, as represented by the Secretary, Dept of Health & Human Services
    Inventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
  • Antibodies for the alpha platelet-derived growth factor receptor
    Patent number: 6660488
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: December 9, 2003
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
  • Antibodies for the alpha platelet-derived growth factor receptor
    Publication number: 20020055129
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.
    Type: Application
    Filed: January 25, 2001
    Publication date: May 9, 2002
    Applicant: The Government of The United States of America, as
    Inventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
  • Attenuated and dominant negative variant cDNAs of Stat6: Stat6b and Stat6c
    Patent number: 6368828
    Abstract: The present invention provides an isolated nucleic acid encoding the polypeptide Stat6b, having an amino acid sequence of Stat6 wherein a deletion in the nucleic acid is present, encompassing the last base pair of codon 39 of Stat6 and continuing through to and including codon 86 of Stat6 and an isolated polypeptide, Stat6b, having an amino acid sequence of Stat6 wherein amino acids 39-86 are deleted at the amino terminus. Also provided is an isolated nucleic acid encoding the polypeptide Stat6c, having an amino acid sequence of Stat6 wherein amino acids 537-564 are deleted and an isolated polypeptide, Stat6c, having an amino acid sequence of Stat6 wherein amino acids 537-564 are deleted. Methods of producing the polypeptide Stat6b and polypeptide Stat6c are also provided, comprising culturing cells comprising nucleic acid encoding the polypeptide Stat6b or the polypeptide Stat6c under conditions whereby the polypeptide Stat6b or the polypeptide Stat6c is produced.
    Type: Grant
    Filed: February 23, 2000
    Date of Patent: April 9, 2002
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: William LaRochelle, Bharvin K. R. Patel, Jacalyn H. Pierce
  • Immunoassays for the alpha platelet-derived growth factor receptor
    Patent number: 6228600
    Abstract: Recombinant DNA technology was used to clone encoding nucleic acids for the human alpha platelet-derived growth factor receptor (PDGF-R type alpha). Peptides corresponding to the predicted sequence of this type and of the PDGF-R type beta were used to elicit antibodies specific for either type of the PDGF-R. Immunoassays are described for determining the level of PDGF-R type alpha in biological samples with the PDGF-R type alpha-specific antibodies.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: May 8, 2001
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
  • Method of detecting the expression of alpha platelet-derived growth factor receptor gene
    Patent number: 5965359
    Abstract: Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used successfully to produce a hitherto unknown type of human Platelet-Derived Growth Factor (PDGF) receptor protein free of other PDGF receptors. These proteins can be produced from DNA segments in cells in various functional forms. These forms variously enable biochemical and functional studies of these novel receptors as well as production of antibodies. Means are described for determining the level of expression of genes for specific types of PDGF receptor proteins, for example, by measuring mRNA in cells with PDGF receptor type-specific DNA probes or by measuring antigen in biological samples with type-specific antibodies.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: October 12, 1999
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Toshimitsu Matsui, Stuart A. Aaronson, Jacalyn H. Pierce
  • DNA encoding an insulin receptor substrate
    Patent number: 5858701
    Abstract: A substantially pure nucleic acid comprising a sequence encoding an IRS-2 polypeptide, a substantially pure preparation of an IRS-2 polypeptide, and related methods.
    Type: Grant
    Filed: October 3, 1994
    Date of Patent: January 12, 1999
    Assignee: Joslin Diabetes Center, Inc.
    Inventors: Morris F. White, Xiao Jian Sun, Jacalyn H. Pierce